Skip navigation

next month. Six-month results from both of our two Phase 3 trials are required for a US NDA application. With favorable results, we plan to file our NDA in the third quarter of 2017. no dataNow, turning to potential new products. An IND opened for a six-month open label investigator-sponsored study of an implant for severe knee osteoarthritis. We’ve been developing this implant with hospitals for special surgery. The surgical screw-type implant, with an embedded Durasert device, provides sustained delivery of a corticosteroid directly through to the joint. Our goal is to provide long-term pain relief, and delay the need for a total knee replacement surgery. What You Need To Know About Astute Astigmatism Products | Madeline Martinez BoxWe look forward to the outcome of this study, and believe this approach could be applied to other types of osteoarthritis.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/edited-transcript-psdv-earnings-conference-060317304.html

Leave a Reply

Your email address will not be published. Required fields are marked *